MARY E. GERRITSEN, PhD.
`
`541 PARROTT DRIVE
`SAN MATEO, CA 94402
`Mobile: 650 520 6039
`Home: 650 348 6492
`EMAIL: meg570@comcast.net
`Website: www.gerritsenconsulting.com
`
`
`
`Profile
`
`Highly motivated scientist and leader with over 25 years of experience in the pharmaceutical and
`biotechnology industry. Broad range of deep expertise in multiple therapeutic areas including oncology,
`inflammation, autoimmune disease, ophthalmology and cardiovascular disease, and experience in the
`identification and preclinical development of both small molecule and protein/antibody based
`therapeutics. Exceptional success record in moving projects from target identification and validation, high
`throughput screening, lead validation, lead optimization, and early clinical development including the
`development and implementation of translational biomarker and pharmacodynamic assays for novel
`targets and novel mechanisms. Strong track record of peer reviewed publications and issued patents.
`Dynamic individual experienced in high level strategic planning, attention to detail, and solving unique and
`difficult challenges. Proven leadership, excellence in motivating and empowering direct and indirect
`reports, and the ability to communicate and present complex data and projects in a clear and
`comprehensive fashion.
`
`Experience
`
`GERRITSEN CONSULTING. SAN MATEO CALIFORNIA 2010-present
`CONSULTING PROFESSOR, DEPARTMENT OF SURGERY, STANFORD UNIVERSITY 2010-present
`
`Independent biotechnology consultant on topics related to biotherapeutics/drug discovery in the
`therapeutic areas of oncology, immuno-oncology, ophthalmology, autoimmune diseases/ inflammation
`and angiogenesis related diseases. I have worked on projects requiring expertise in both small molecule
`and biologic drugs including those targeting protein kinases, matrix metalloproteinases, phosphatase,
`steroid and other nuclear receptors, CAR-T cell therapy, and novel small molecule approaches such as
`irreversible and covalent reversible inhibitors, targeted therapies, and bromo-domain targeted therapies.
`Projects involve assessment of research strategy, target selection and intellectual property positions,
`compound selection criteria, data quality control and management, selection and development of
`protocols for cell based assays, pharmacodynamic assays and clinical biomarker studies, translational
`biology approaches for patient stratification, preclinical assays that can be used to identify potential
`patient phenotype/genotypes, screening contract research organizations and academic laboratories for
`contracts and collaborations, establishing collaborations and work orders, preparation and editing of
`investigator brochures, IND documents, clinical protocols, SOPs for clinical trials, manuscripts, poster and
`meeting presentations, and evaluation of research and pipeline portfolio strategies for both venture capital
`firms and companies interested in in-licensing, partnering or acquisition of new compounds/technologies
`or companies. Consultant on various projects at laboratories in department of vascular surgery at
`Stanford.
`
`EXELIXIS, SOUTH SAN FRANCISCO, CA 2004-2010
`VICE PRESIDENT
`MOLECULAR AND CELLULAR PHARMACOLOGY
`
`Biotechnology company focused on the discovery and development of small molecular therapeutics for
`the treatment of oncology and metabolic disease. Reported to the Executive Vice President of Research
`and Chief Scientific officer.
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`Joining Petitioner: Apotex
`
`

`

`• Leader of interdisciplinary teams at all stages of preclinical to early clinical development. Strong
`track record with increasing responsibility, promoted from Senior Director to Executive Director
`(2007) and to Vice President (2009). Managed a department of 82 scientists (30 Ph.Ds) with 6
`direct reports (Senior Director, 4 Directors, and 1 Administrative Assistant). Prepared and
`managed multi-million dollar budgets, set priorities and managed costs while remaining extremely
`productive.
`
`• Led the divisions that were responsible for different roles in drug discovery including target
`identification and validation, robotic cell culture, cell line acquisition and banking, cell based
`mechanistic and phenotypic assays and pharmacodynamic studies, and translational medicine.
`
`• Led the biomarker group (~10 PhDs/RAs) responsible for identification, validation and assay of
`clinical biomarkers to support ongoing clinical trials (Phase I and Phase II). Developed and
`implemented a number of novel biomarker studies that enabled identification of
`pharmacodynamics activity for drugs in early clinical development.
`
`• Responsible for the all cell biology and pharmacodynamic sections of multiple INDS: XL228
`(IGF1R/Bcr-Abl), XL281 (RAF), XL765 (PI3K/MTOR), XL147 (PI3K), XL888 (HSP90), XL139
`(hedgehog), XL019 (JAK2), XL518 (MEK), XL418 (AKT), XL388 (TORC1/TORC2), XL413
`(CDC7), XL541(S1P1R), XL499 (PI3Kγ).
`
`• Supervised and led research team leaders in early target validation, lead validation and lead
`optimization for both oncology and inflammation/autoimmune disease indications around various
`molecular target classes including protein and lipid kinases, sphingomyelinase, ceramide
`synthase, methyltransferase, dehydrogenase, ATPase, and GPCRs.
`
`• Member of the Research and Development Management Committee with responsibility for key
`strategic decisions.
`
`• Provided project updates and strategic evaluations to senior management (CSO, CEO,
`President) and board of directors.
`
`• Spearheaded the implementation of the “Post-Development Compound” characterization teams
`that further characterized mechanism of action, combination studies, tumor cell line profiling, and
`other studies used to assist the clinical project teams in patient stratification strategies for XL
`compounds. These studies were also instrumental in Exelixis partnering and business
`development activities.
`
`• Recruited numerous scientists and research associates to build up key areas of expertise in
`molecular and cellular pharmacology
`
`• Built a world class repository of cancer cell lines integrated with gene expression, protein
`expression and phosphorylation, and associated sequencing data (mutations, amplifications,
`translocations). Implemented the utilization of these cell lines and associated data to profile
`development compounds and identify potential sensitive tumor types.
`
`• Brought in multiple bone marrow and primary cell/tumor specimens to evaluate effects of our DC
`compounds on stem cell properties. Used these and established cell lines and tissue samples to
`identify and validate biomarkers for Phase I and II clinical trials.
`
`• Co-authored with colleague David Matthews, “Targeting Protein Kinases for Cancer Therapy”
`(Wiley Press, 2010), a comprehensive, 700+ page book that featured an overview of protein
`kinases, their structure and function, and the drugs that inhibit them.
`
`FRAZIER HEALTH CARE VENTURES, PALO ALTO, CA 2003-2004
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`Joining Petitioner: Apotex
`
`

`

`CONSULTANT
`
`One of the leading providers of venture and growth equity capital to emerging biopharma, medical device
`and healthcare service companies. As a consultant, involved in the founding of Macusight, an
`angiogenesis company focused on age-related macular degeneration and diabetic macular edema.
`
`• Established collaborations and agreements with academic and contract labs to move product
`forward into IND stage.
`
`• Made key scientific presentations to venture firms to enable first round financing.
`
`• Key inventor on IP that enabled the funding and founding of the company.
`
`MILLENNIUM PHARMACEUTICALS, SOUTH SAN FRANCISCO, CA 2002-2003
`SENIOR DIRECTOR
`VASCULAR BIOLOGY
`
`Formerly COR Therapeutics, Millennium South San Francisco was focused on cardiovascular disease,
`with two major areas of therapeutic focus: platelet biology and atherosclerosis.
`
`• Developed strategic plan for vascular biology at Millennium.
`
`• Supervised project leaders on three small molecule discovery programs (Targets: GPCR, Growth
`Factor Receptor, Transcription Factor) at different stages-hit to lead, lead optimization and high
`throughput screening.
`
`• Supervised multiple functional groups-vascular biology, functional genomics and histology core.
`
`•
`
`Initiated collaborations with academic laboratories (to bring in human tissue specimens and timed
`specimens from animal models of vascular disease) to enable genomic screens in key
`therapeutic areas.
`
`• Supervised vascular biology target discovery group, responsible for identification of screening
`targets for Millennium partners (large Pharma companies)
`
`• Presentations to senior management.
`
`GENENTECH SOUTH SAN FRANCISCO, CA 1997-2001
`SENIOR SCIENTIST/ASSOCIATE DIRECTOR
`DEPARTMENT OF CARDIOVASCULAR RESEARCH
`
`One of the founders of the biotechnology industry, Genentech has been delivering on the promise of
`biotechnology for more than 30 years. Known throughout the industry as a company using human genetic
`information to discover, develop, manufacture and commercialize medicines to treat patients with serious
`or life-threatening medical conditions.
`
`
`• Coordinated screening efforts of several groups in vascular biology related to endothelial biology
`for identification of new activities for novel secreted proteins and transmembrane proteins in the
`areas of angiogenesis and atherosclerosis.
`
`• Senior investigator in angiogenesis research, identifying novel targets for protein based
`therapeutics.
`
`• Used genomics, protein analysis, tissue microarrays, gene-calling, in situ hybridization and other
`cutting edge techniques to identify and validate targets.
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 3
`
`Joining Petitioner: Apotex
`
`

`

`• Recruited and supervised research associates, post-doctoral fellows, summer interns, visiting
`scientists and a senior scientist.
`
`• Presentations to senior management and board of directors.
`
`•
`
` Filed multiple patent applications (over 1000, with over 40 now issued) and published a number
`of highly cited articles in the field of angiogenesis.
`
`HARVARD MEDICAL SCHOOL/BRIGHAM AND WOMEN’S HOSPITAL. 1996
`VISITING SCIENTIST
`DEPARTMENT OF PATHOLOGY, VASCULAR RESEARCH DIVISION
`
`Training in molecular pathology, cloning, expression, and gene promoter analysis. First author or senior
`author of several highly cited publications arising from the sabbatical. Participated in medical grand
`rounds, and pathology resident training.
`
`
`BAYER PHARMACEUTICALS (FORMERLY MILES PHARMACEUTICALS), WEST HAVEN CT 1990-
`1997
`PRINCIPAL STAFF SCIENTIST AND GROUP LEADER
`INSTITUTE FOR INFLAMMATION AND AUTOIMMUNITY
`
`North American site for large pharma company specializing in small molecule drug discovery in the areas
`of oncology, osteoporosis, osteoarthritis, metabolic disease and autoimmunity/inflammation.
`
`
`• Led screening efforts for small molecule inhibitors of leukocyte adhesion, cyclo-oxygenase, and
`cytokine release/action.
`
`• Therapeutic thought leader for inflammation/autoimmunity and responsible for development of
`strategic inflammatory and autoimmune disease research plan and competitive assessment.
`
`• Played a key role in establishing academic and industrial collaborations/contracts for tissue
`acquisition of synovial fluid, synovial membranes, cartilage and related tissues from RA and OA
`patients for target discovery and assay development.
`
`• Developed collaborations with leading laboratories in leukocyte adhesion/recruitment
`
`• First to develop methods to isolate and culture human synovial microvessel endothelial cells and
`use them in drug screens to identify potential compounds for drug development.
`
`•
`
`Identified first inhibitor of NF-KB induced gene expression. Drug was later shown to be a specific
`and irreversible inhibitor of the inflammasome
`
`• Presentations and project updates to senior management in US and Germany.
`
`•
`
` Supervised 6 laboratories (6 Ph.D. scientists and 18-25 research associates and post-doctoral
`fellows).
`
`NEW YORK MEDICAL COLLEGE, VALHALLA NY 1980-1989
`ASSOCIATE PROFESSOR OF PHYSIOLOGY
`
` A
`
` large private health university with a school of medicine, school of health sciences and a graduate
`school of basic medical sciences. As a member of the faculty of the department of physiology,
`responsible for teaching endocrinology and cardiovascular physiology to medical students and graduate
`students.
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 4
`
`Joining Petitioner: Apotex
`
`

`

`• Established research program in endothelial biology, receiving grant support from NIH, AHA and
`other state and national funding agencies. Research area focus on endothelial biology,
`eicosanoid biochemistry, and cellular models of endothelial dysfunction with relevance to
`inflammation, atherosclerosis, hypertension, ophthalmology and diabetes.
`
`• One of the first laboratories to develop methodology to isolate and culture endothelial cells from
`the microvasculature of animal and human tissues (lung, heart, brain, muscle, retina), and to
`demonstrate that “all endothelial cells are not created equal”.
`
`• Supervised graduate students, post-doctoral fellows visiting scientists and summer medical
`student interns.
`
`• Developed methods for the analysis of intraocular fluids and first to demonstrate the presence
`interleukin 6 and other cytokines in samples from patients with proliferative vitreoretinopathy and
`diabetic renal disease
`
`•
`
`In collaboration with investigators at Boehringer Ingleheim, developed a primate model of asthma,
`now used by many pharmaceutical companies for screening
`
`
`Education
`
`Bachelor of Science. Honors major in Zoology, graduating summa cum laude. University of Calgary
`1975
`
`Ph.D. Endocrinology and Pharmacology University of Calgary 1978
`
`Post-doctoral studies in Pharmacology University of California, San Diego. 1978-1980
`
`Visiting Scientist, Harvard Medical School, and Brigham and Women’s Hospital, Department of
`Pathology. 1996
`
`Advanced Course in Immunology, Stanford Medical School and the American Association of
`Immunology. 2002
`Publications and Patents
`
`Over 100 publications in peer reviewed journals, numerous book chapters and three full length books.
`Over 1000 patent applications with 49 issued patents.
`Awards and Honors
`
`• Province of Alberta Graduate Scholar 1976
`• Medical Research Council Studentship 1976-1978
`• Isaac Walton Killam Scholar and Merit Award 1977,1978
`• Medical Research Council Fellow 1978-1980
`• Alexander and Alexandrine Sinsheimer Scholar 1981, 1982
`• Pharmacia Young Investigator Award, Microcirculatory Society 1983
`• Mary Weideman Award, Microcirculatory Society 1984
`• NIH Research Career Development Award 1987-1992
`• Miles Science Award 1992
`• Kurt Weiderhelm Award, Microcirculatory Society 1998
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 5
`
`Joining Petitioner: Apotex
`
`

`

`• Award named after me (Gerritsen Award), awarded annually by the Microcirculatory Society
`• Recipient of 2010 PROSE award for the best book in Biosciences and Neurosciences (Awarded to
`Targeting Protein Kinases for Cancer Therapy, D.J. Matthews and M. E Gerritsen, 2010. Wiley
`Press)
`
`
`Related Professional Activities
`
`
`• Co-organizer, Keystone Conferences (Oxidant Stress, Angiogenesis)
`• Program Committees: International Microcirculatory Meeting, International Vascular Biology
`Meetings, Blood Vessel Club, AHA angiogenesis meetings, ATVB meetings, NAVBO meetings
`• NIH Study Section Member: Pathology A 1993-2000
`• Study Section Member, NIH SCOR and PPG grants on hypertension, oncology, angiogenesis,
`atherosclerosis
`• External Scientific Advisory Committee, Institute for Medicine and Engineering, University of
`Pennsylvania
`• Editorial Boards: Microcirculation, Microvascular Research, Atherosclerosis, Thrombosis and
`Vascular Biology, Journal of Cardiovascular Pathobiology
`• One of the founders, President, Vice-President, Board of Directors (various times), Newsletter
`editor, Development Committee, North American Vascular Biology Organization (NAVBO)
`• Council, Microcirculatory Society
`• Founding Editor and Editor in Chief, Microcirculation, the official journal of the Microcirculatory
`Society
`• Consultant on various academic program projects, RO1 grants, SCOR grants (fields: vascular
`biology, angiogenesis, prostanoids, endothelial cell biology, aortic aneurysm); also consultant (at
`various times) to biotech and pharma companies ranging in size from 3 to over 1000 employees.
`
`
`Grants from the NIH, American Heart Association, Fight for Sight etc
`
`National Instituties of Health
`
`
`
`
`
`
`NIH New Investigator Award "Cerebral Microvessels "
`NIH HLBI RO1 Grant "Glucocorticoids and Microvessel Endothelium"
`NIH EI RO1 Grant "Retinal Endothelial Cells"
`Research Career Development Award
`
`NIH HLBI RO1 grant "Glucocorticoids and Microvessel Endothelium"
`
`1981-1984
`1985-1988
`1985-1988
`1986-1989
`1990-1996
`
`
`
`Other Agencies
`
`
`
`1981-1984
`
`American Heart Association Grant-in-Aid "Isolation and Characterization of
`Endothelial Cells from Cardiac Muscle"
`American Diabetes Association Grant-in-Aid "Effects of High Glucose
`on Retinal Microvascular Endothelial Cells"
`Westchester Heart Association Grant-in-Aid " Effects of High Glucose on Cardiac
`Muscle Microvessel Endothelial Cells"
`New York State Health Research Council Grant-in-
`1984-1985
`Aid "Eicosanoid Metabolism in Cardiac Muscle Microvessel
`
`
`
` Endothelium"
`1986
`
`Boehringer Ingelheim Grant-In-Aid "Isolation of a Leukocyte
`
`
`Regulatory Factor from Microvessel Endothelium"
`1990
`
`Miles Inc. Grant in Aid. Fellowship support for Robert Mannix
`1989
`
`Fight for Sight Fellowship (sponsor for Julio Rimarachin)
`New York Eye and Ear Fellowship (sponsor for Julio Rimarachin)
`1989
`
`
`
`1984
`
`
`1984-1986
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 6
`
`Joining Petitioner: Apotex
`
`

`

`
`
`
`Selected Articles
`
`Xu B, Ida Y, Glover KJ, Ge Y, Wang Y, Xuan H, Hu X, Tanaka H, Wang W, Fujimura N, Miyata M, Shoji
`T, Gua J, Zheng X, Gerritsen M, Kuo C, Michie S, and Dalman RL. (2019) Inhibition of VEGF
`(Vascular Endothelial Growth Factor)-A or its receptor activity suppresses experimental aneurysm
`progression in the aortic elastase infusion model. Arteriosclerosis Thrombosis and Vascular
`Biology 39: 1652-1666.
`
`
`Nairismägi, M-L, Gerritsen, ME, Li ZM, Wijaya JC, Chia, BKH, Lim JQ, Laurensia Y, Burton ,Yeoh KW,
`Yao XS, Pang WL, Bisconte A, Hill RJ, Bradshaw JM, Song TLL, Huang D, Ng CCY,
`Rajasegaran V, Tan QQ, Lim ST, Teh BT, Ong CK and Tan J. (2018)Oncogenic Activation of
`JAK3-STAT Signaling Confers Clinical Sensitivity to PRN371, a Novel Selective and Potent JAK3
`Inhibitor, in Natural Killer/T-cell Lymphoma.Leukemia 32: 1147-1156.
`
`
`Venetsanakos E, Brameld, K, Phan, VT, Verner E, Owens TD, Xing Y, Tam D, LaStant, J, Leung K, Karr
`DE, Hill R, Gerritsen ME, Goldstein DM, Funk JO, and Bradshaw MJ. (2017)The Irreversible
`Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of
`FGFR after Drug Clearance. Molecular Cancer Therapeutics 16: 2668-2676.
`
`
`Bramfeld, KA, Owens TD, Verner, E Venesanakos, E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J,
`LsStant J, Loughead DG, Ton T, Karr DE, Gerritsen ME, Goldstein DM and Funk JO. Discovery
`of the irreversible covaltent FGFR inhibitor 8-(3-(4-acryloylpiperazine-1-yl)propyl)-6-(2,6-dichloro-
`3,5-dimethoxyphenyl)-2-(methlamino)oyrido [2,3-d]pyrimidin-7(8H)-one (PRN1371) for the
`treatment of solid tumors. J Med Chem 60:6516-6527, 2017.
`
`
`Venetsanakos E, Bradshaw JM, Goldstein DM, Leung K, Karr D, Gerritsen ME, Xing Y, LaStant J, Nunn
`PA, Shu J, Bommireddi A, Gourlay SG, Funk JO, Brameld KA. (2016) PRN1371, an irreversible,
`covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor
`models. Presented at American Association for Cancer Research Annual Meeting, New Orleans,
`LA, April 2016
`
`
`Phan VT, Verner E, Gerritsen M, Bradshaw JM, Goldstein DM, Hill RJ, Karr D, LaStant J, Nunn P, Tam D,
`Shu J, Funk JO, Brameld KA.(2014) Irreversible covalent pan-FGFR Inhibitors are highly
`efficacious against FGFR-dependent cancers. Presented at EORTC-NCI-AACR 2014, Barcelona,
`November 18-21.
`
`
`Bradshaw, JM, McFarland, JM, Paavilainen, VO, Bisconte, A., Tam, D., Phan, VT, Romanov, S, Finkle, D,
`Shu, J, Patel, V, Ton, T, Li, X, Loughhead, DG, Nunn, PA, Karr, DE, Gerritsen, ME, Funk, JO,
`Owens, TD, Verner, E, Brameld, KA, Hill, RJ, Goldstein, DM and Taunton, J. (2015) Prolonged
`and tunable residence time using reversible covalent kinase inhibitors. Nature Chemical Biology
`11.7 525-531
`
`
`Rouer, M, Xu, BH, Xuan, HJ, Tanaka, H, Fujimura, N Glover, KJ, Furusho, Y, Gerritsen, M and Dalman,
`RL. (2014) Rapamycin limits the growth of established experimental abdominal aortic aneurysms.
`Eur J Vasc Endovasc Surg 47:493-500
`
`
`Phan, VT, Verner, E, Gerritsen, M, Bradshaw, JM, Goldstein, DM, Hill, RJ, Karr, D, LaStant, J, Nunn, P,
`Tam, D, Shu, J, Funk, JO and Brameld, KA.( 2014) Irreversible covalent pan-FGF inhibitors are
`highly efficacious against FGFR-dependent cancer. EORTC Abstr 483
`
`
`Xu, B, Fujiyama, N, Glover, K, Xuan, H, Furusho, Y, Tanaka, H, Gerritsen, M and Dalman, R. (2014).
`Myeloid cell-specific VEGF-A deletion inhibits experimental abdominal aortic aneurysms.
`Arteriosclerosis, Thrombosis and Vascular Biology 34:A305
`
`
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 7
`
`Joining Petitioner: Apotex
`
`

`

`Glover, KJ, Xu, B, Iida, Y, Xuan, H,m Tanaka, H, Wang, W, Fujimura, N, Gerritsen, M and Dalman, RL.
`(2013). VEGF-A neutralization suppresses experimental abdominal aortic aneurysm (AAA)
`formation. J Vasc Surgery 57:S p84S
`
`
`Wang, W., Xu, B, Xuan, H, Tanaka, H., Rouer, M, Glover, KJ, Fujimura, N, Hu, X, Gerritsen, M, Michie,
`SA and Dalman, RL.(2013) Inhibition of hypoxia inducible factor (HIF)-1a suppresses formation
`and progression of experimental abdominal aortic aneurysms (AAAs). J Vasc Surgery 57:S p83S-
`84S
`
`
`Iida, Y, Xu, B, Hu, X, Chow, V, Yuan, R., Gerritsen, M, Ogino, H and Dalman, RL. (2012). Angiogenesis
`inhibitor sunitinib suppresses the formation and progression of experimental abdominal aortic
`aneurysm. J Vasc Surgery, Vascular Annual Meeting, PS216.
`
`Xu, B., Iida, Y,Hu, X, Xuan, H, Gerritsen, M. and Dalman, RL. (2012) Model-dependent influence of prior
`splenectomy on experimental abdominal aortic aneurysm progression. Arteriosclerosis,
`Thrombosis and Vascular Biology 32:A102, 2012
`
`
`Lyman, SK, Suzanne Crawley, S Gong, R, Adamkewicz, J, McGrath, G, Chew, J, Choi, J Holst, C,
`Goon, L, Detmer, S, Vaclavikova, J, Gerritsen, ME and Blake, RA High-content, high-throughput
`analysis of cell cycle pertubations induced by the HSP90 inhibitor XL888 Plos one 6:e17692,
`2011
`
`
`Kim DD, Kleinman DM, Kanetaka T, Gerritsen ME, Nivaggioli T, Weber D, Duran WN. (2010) Rapamycin
`Inhibits VEGF-Induced Microvascular Hyperpermeability In Vivo. Microcirculation 17:128-136
`
`
`Trowe T, Boukouvala S, Calkins K, Cutler RE, Jr., Fong R, Funke R, Gendreau SB, Kim YD, Miller N,
`Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS. (2008)
`EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic
`transformation. Clin Cancer Res 14:2465-2475
`
`
`Gerritsen ME. (2005a) HGF and VEGF: a dynamic duo. Circ Res 96:272-273
`
`Gerritsen ME, Wagner GF. (2005) Stanniocalcin: no longer just a fish tale. Vitam Horm 70:105-135
`
`Gerritsen ME. (2005b) Genetic variations in vascular endothelial growth factor and endothelial nitric oxide
`synthase and their contributions to human disease. Microcirculation 12:129-140
`
`
`Shin HY, Schwartz EA, Bizios R, Gerritsen ME. (2004) Receptor-mediated basic fibroblast growth factor
`signaling regulates cyclic pressure-induced human endothelial cell proliferation. Endothelium
`11:285-291
`
`
`Zlot C, Ingle G, Hongo J, Yang S, Sheng Z, Schwall R, Paoni N, Wang F, Peale FV, Jr., Gerritsen ME.
`(2003) Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to
`hepatocyte growth factor. J Biol Chem 278:47654-47659
`
`
`Yang RB, Ng CK, Wasserman SM, Komuves LG, Gerritsen ME, Topper JN. (2003) A novel interleukin-17
`receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic
`fibroblast growth factor-induced signaling. J Biol Chem 278:33232-33238
`
`
`Shin HY, Bizios R, Gerritsen ME. (2003) Cyclic pressure modulates endothelial barrier function.
`Endothelium 10:179-187
`
`
`Gerritsen ME, Soriano R, Yang S, Zlot C, Ingle G, Toy K, Williams PM. (2003a) Branching out: a
`molecular fingerprint of endothelial differentiation into tube-like structures generated by Affymetrix
`oligonucleotide arrays. Microcirculation 10:63-81
`
`
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 8
`
`Joining Petitioner: Apotex
`
`

`

`Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S. (2003b) Using gene expression profiling to
`identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular
`endothelial growth factor in human endothelial cells. Br J Pharmacol 140:595-610
`
`
`Egginton S, Gerritsen M. (2003) Lumen formation: in vivo versus in vitro observations. Microcirculation
`10:45-61
`
`
`Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A, Gerritsen ME. (2002) Vascular
`endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of
`KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 22:1797-1803
`
`
`Shin HY, Gerritsen ME, Bizios R. (2002a) Regulation of endothelial cell proliferation and apoptosis by
`cyclic pressure. Ann Biomed Eng 30:297-304
`
`
`Shin HY, Smith ML, Toy KJ, Williams PM, Bizios R, Gerritsen ME. (2002b) VEGF-C mediates cyclic
`pressure-induced endothelial cell proliferation. Physiol Genomics 11:245-251
`
`
`Paoni NF, Peale F, Wang F, Errett-Baroncini C, Steinmetz H, Toy K, Bai W, Williams PM, Bunting S,
`Gerritsen ME, Powell-Braxton L. (2002) Time course of skeletal muscle repair and gene
`expression following acute hind limb ischemia in mice. Physiol Genomics 11:263-272
`
`
`Kiosses WB, Hood J, Yang S, Gerritsen ME, Cheresh DA, Alderson N, Schwartz MA. (2002) A dominant-
`negative p65 PAK peptide inhibits angiogenesis. Circ Res 90:697-702
`
`
`Gerritsen ME, Peale FV, Jr., Wu T. (2002a) Gene expression profiling in silico: relative expression of
`candidate angiogenesis associated genes in renal cell carcinomas. Exp Nephrol 10:114-119
`
`
`Gerritsen ME, Soriano R, Yang S, Ingle G, Zlot C, Toy K, Winer J, Draksharapu A, Peale F, Wu TD,
`Williams PM. (2002b) In silico data filtering to identify new angiogenesis targets from a large in
`vitro gene profiling data set. Physiol Genomics 10:13-20
`
`
`Filvaroff EH, Guillet S, Zlot C, Bao M, Ingle G, Steinmetz H, Hoeffel J, Bunting S, Ross J, Carano RA,
`Powell-Braxton L, Wagner GF, Eckert R, Gerritsen ME, French DM. (2002) Stanniocalcin 1 alters
`muscle and bone structure and function in transgenic mice. Endocrinology 143:3681-3690
`
`
`Chan-Ling T, Gerritsen ME, Hill CE, Kubes P, Perry M. (2002) Microcirculation down under. Trends
`Pharmacol Sci 23:106-108
`
`
`Yang S, Xin X, Zlot C, Ingle G, Fuh G, Li B, Moffat B, de Vos AM, Gerritsen ME. (2001) Vascular
`endothelial cell growth factor-driven endothelial tube formation is mediated by vascular
`endothelial cell growth factor receptor-2, a kinase insert domain-containing receptor. Arterioscler
`Thromb Vasc Biol 21:1934-1940
`
`
`Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME. (2001)
`Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in
`vitro and in vivo. Am J Pathol 158:1111-1120
`
`
`Peale FV, Jr., Gerritsen ME. (2001) Gene profiling techniques and their application in angiogenesis and
`vascular development. J Pathol 195:7-19
`
`
`Langley RR, Carlisle R, Ma L, Specian RD, Gerritsen ME, Granger DN. (2001) Endothelial expression of
`vascular cell adhesion molecule-1 correlates with metastatic pattern in spontaneous melanoma.
`Microcirculation 8:335-345
`
`
`Gerritsen ME. (2001) Angiogenesis and chronic disease. 24-29 April 2001. Trends Mol Med 7:333-334
`
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 9
`
`Joining Petitioner: Apotex
`
`

`

`Li B, Fuh G, Meng G, Xin X, Gerritsen ME, Cunningham B, de Vos AM. (2000) Receptor-selective
`variants of human vascular endothelial growth factor. Generation and characterization. J Biol
`Chem 275:29823-29828
`
`
`Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, Schoenfeld J, Grimaldi CJ, Peale F,
`Draksharapu A, Lewin DA, Gerritsen ME. (2000) Gene expression profiling in an in vitro model of
`angiogenesis. Am J Pathol 156:1887-1900
`
`
`Yang S, Graham J, Kahn JW, Schwartz EA, Gerritsen ME. (1999) Functional roles for PECAM-1 (CD31)
`and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen
`gels. Am J Pathol 155:887-895
`
`
`Xin X, Yang S, Kowalski J, Gerritsen ME. (1999) Peroxisome proliferator-activated receptor gamma
`ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116-9121
`
`
`Schwartz EA, Bizios R, Medow MS, Gerritsen ME. (1999) Exposure of human vascular endothelial cells
`to sustained hydrostatic pressure stimulates proliferation. Involvement of the alphaV integrins.
`Circ Res 84:315-322
`
`
`Mori N, Horie Y, Gerritsen ME, Anderson DC, Granger DN. (1999a) Anti-inflammatory drugs and
`endothelial cell adhesion molecule expression in murine vascular beds. Gut 44:186-195
`
`
`Mori N, Horie Y, Gerritsen ME, Granger DN. (1999b) Ischemia-reperfusion induced microvascular
`responses in LDL-receptor -/- mice. Am J Physiol 276:H1647-1654
`
`
`Langley RR, Russell J, Eppihimer MJ, Alexander SJ, Gerritsen M, Specian RD, Granger DN. (1999)
`Quantification of murine endothelial cell adhesion molecules in solid tumors. Am J Physiol
`277:H1156-1166
`
`
`Eppihimer MJ, Russell J, Langley R, Gerritsen M, Granger DN. (1999) Role of tumor necrosis factor and
`interferon gamma in endotoxin-induced E-selectin expression. Shock 11:93-97
`
`
`Carley W, Ligon G, Phan S, Dziuba J, Kelley K, Perry C, Gerritsen ME. (1999) Distinct ICAM-1 forms and
`expression pathways in synovial microvascular endothelial cells. Cell Mol Biol (Noisy-le-grand)
`45:79-88
`
`
`Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, Gerritsen ME, Collins T.
`(1998) Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by
`CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 273:29291-29294
`
`
`Gerritsen ME, Shen CP, Perry CA. (1998) Synovial fibroblasts and the sphingomyelinase pathway:
`sphingomyelin turnover and ceramide generation are not signaling mechanisms for the actions of
`tumor necrosis factor-alpha. Am J Pathol 152:505-512
`
`
`Gerritsen ME. (1998a) Benjamin W. Zweifach 1911-1997. Microcirculation 5:3-4
`
`Gerritsen ME. (1998b) Flavonoids: inhibitors of cytokine induced gene expression. Adv Exp Med Biol
`439:183-190
`
`
`Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME. (1997) Novel inhibitors
`of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule
`expression show anti-inflammatory effects in vivo. J Biol Chem 272:21096-21103
`
`
`Komatsu S, Flores S, Gerritsen ME, Anderson DC, Granger DN. (1997) Differential up-regulation of
`circulating soluble and endothelial cell intercellular adhesion molecule-1 in mice. Am J Pathol
`151:205-214
`
`Mylan Exhibit 1061
`Mylan v. Regeneron, IPR2021-00881
`Page 10
`
`Joining Petitioner: Apotex
`
`

`

`
`Hoyt DG, Rizzo M, Gerritsen ME, Pitt BR, Lazo JS. (1997) Integrin activation protects pulmonary
`endothelial cells from the genotoxic effects of bleomycin. Am J Physiol 273:L612-617
`
`
`Horie Y, Chervenak RP, Wolf R, Gerritsen ME, Anderson DC, Komatsu S, Granger DN. (1997)
`Lymphocytes mediate TNF-alpha-induced endothelial cell adhesion molecule expression: studies
`on SCID and RAG-1 mutant mice. J Immunol 159:5053-5062
`
`
`Henninger DD, Panes J, Eppihimer M, Russell J, Gerritsen M, Anderson DC, Granger DN. (1997a)
`Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol
`158:1825-1832
`
`
`Henninger DD, Gerr